BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Frequently asked questions
What sector does BioLineRx Ltd (BLRX) operate in?
BioLineRx Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is BioLineRx Ltd (BLRX) current stock price?
As of the latest data, BioLineRx Ltd stock price is $2.76, with a previous close of $2.72. BioLineRx Ltd gained $0.04 in the last trading session, representing a 1.52% increase.
What is BioLineRx Ltd (BLRX) current market capitalization?
BioLineRx Ltd market cap is approximately 12.01 million.
What is BioLineRx Ltd (BLRX) EBITDA?
BioLineRx Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.25 million.
Does BioLineRx Ltd (BLRX) pay dividends?
No. BioLineRx Ltd does not pay a dividend.
How did BioLineRx Ltd (BLRX) perform in its most recent earnings report?
In the last report (March 31, 2026), BioLineRx Ltd posted an EPS surprise of 44.03% and a revenue surprise of 39.07%.
When is BioLineRx Ltd (BLRX) next earnings report?
BioLineRx Ltd is expected to release its next earnings report on June 30, 2026.
What is BioLineRx Ltd (BLRX) beta (volatility) score?
BioLineRx Ltd has a beta of 0.711, indicating lower volatility than the overall market.
